Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: Overcoming the pharmacological and pharmacoeconomic limitations of existing therapies

Mayo Clinic Proceedings

Volumn 82, Issue 11, 2007, Pages 1371-1380

  Wish, Jay B ^a,c   Coyne, Daniel W ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PRI DEXTRA; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANEMIA; CANCER PATIENT; CHRONIC KIDNEY DISEASE; CLINICAL EXAMINATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IRON THERAPY; KIDNEY FAILURE; MEDLINE; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; QUALITY OF LIFE; REFERENCE VALUE; REVIEW; SURVIVAL; THROMBOEMBOLISM; UNITED STATES;

EID: 35848964081     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.11.1371     Document Type: Review

References (66)

1. National Kidney Foundation. Chronic kidney disease. Available at: www.kidney.org/kidneyDisease/ckd/index.cfm. Accessed August 13, 2007.
2. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501-1510.
3. National Kidney Foundation. Kidney Early Evaluation Program. Am J Kidney Dis. 2005;45(2, suppl 2):S1-S135.
4. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease [published correction appears in Am J Kidney Dis. 2006;48(3):518] Am J Kidney Dis. 2006;47(5, suppl 3):S11-S145.
5. National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530.
6. Drueke TB, Locatelli F, Clyne N, et al, CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-2084.
7. Singh AK, Szczech L, Tang KL, et al, CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355(20):2085-2098.
8. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369(9559):381-388.
9. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC. Haemoglobin targets: we were wrong, time to move on. Lancet. 2007; 369(9559):346-350.
10. Jensen JD, Madsen JK, Jensen LW, Pedersen EB. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol. 1994;5(2):177-185.
11. Snively CS, Gutierrez C. Chronic kidney disease: prevention and treatment of common complications. Am Fam Physician. 2004;70(10):1921-1928.
12. Popovsky MA, Ransil BJ. Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. Immunohematol. 1996;12(1):1-3.
13. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001;16(suppl 3):3-13.
14. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31(4):290-299.
15. Deicher R, Horl WH. Differentiating factors between erythropoiesis- stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs. 2004;64(5):499-509.
16. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991;50(6):702-712.
17. Padhi D, Ni L, Cooke B, Marino R, Jang G. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet. 2006;45(5):503-510.
18. Aranesp (darbepoetin alfa) for injection [prescribing information]. Thousand Oaks, CA: Amgen Inc, 2007. Available at: www.aranesp.com/professional /prescribing_information.jsp. Accessed September 24, 2007.
19. Procrit (epoetin alfa) for injecton [prescribing information]. Thousand Oaks, CA: Amgen Inc. Distributed by Ortho Biotech Products, LP: Raritan, NJ, 2007. Available at: www.procrit.com/ppi.pdf. Accessed September 24, 2007.
20. Epogen (epoetin alfa) for injection [prescribing information]. Thousand Oaks, CA: Amgen Inc, 2007. Available at: www.epogen.com/pdf/epogen_pi .pdf. Accessed September 24, 2007.
21. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40(1):110-118.
22. Germain M, Ram CV, Bhaduri S, Tang KL, Klausner M, Curzi M. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant. 2005 Oct;20(10):2146-2152. Epub 2005 Jun 28.
23. Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol. 2005;64(2):113-123.
24. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant. 2004;19(4):898-903.
25. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005;63(5):327-334.
26. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18(2):353-361.
27. Provenzano R, Garcia-Mayol L, Suchinda P, et al, POWER Study Group. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol. 2004;61(6):392-405.
28. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-78.
29. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992-1000.
30. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17(4):1181-1191.
31. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584-590.
32. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005 Jul;16(7):2180-2189. Epub 2005 May 18.
33. Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis. 1994;24(5):777-784.
34. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66(2):753-760.
35. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77(2):176-185.
36. Frank H, Heusser K, Hoffken B, Huber P, Schmieder RE, Schobel HP. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney Int. 2004;66(2):832-840.
37. Ayus JC, Go AS, Valderrabano F, et al, Spanish Group for the Study of the Anemia and Left Ventricular Hypertrophy in Pre-dialysis Patients. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int. 2005;68(2):788-795.
38. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18(1):141-146.
39. Ritz E, Laville M, Bilous RW, et al, ACORD Investigators and Coordinators. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49(2):194-207.
40. Miyashita K, Tojo A, Kimura K, et al. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res. 2004;27(2):79-84.
41. Ng T, Marx G, Littlewood T, Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad Med J. 2003;79(933):367-376.
42. St Peter W. Collaborative anemia management in chronic kidney disease patients: a pharmacist's viewpoint. Available at: http://www.medscape.com/ viewarticle/546165_5. Accessed August 15, 2007.
43. Beveridge RA, Rifkin RM, Moleski RJ, et al. Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy. 2003;23(12, pt 2):101S-109S.
44. Coyne DW. Practice recommendations based on low, very low, and missing evidence. Clin J Am Soc Nephrol. 2007;2(1):11-12.
45. Coyne DW. Influence of industry on renal guideline development. Clin J Am Soc Nephrol. 2007;2(1):3-7.
46. Van Wyck D, Eckardt K-U, Uhlig K, Rocco M, Levin A. Appraisal of evidence and control of bias in the kidney disease outcomes quality initiative guideline development process. Clin J Am Soc Nephrol. 2007;2(1):8-10.
47. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet. 2006;368(9539): 947-953.
48. Macdougall IC. Individualizing target haemoglobin concentrations - tailoring treatment for renal anaemia. Nephrol Dial Transplant. 2001;16(suppl 7):9-14.
49. Muirhead N. Individualizing anaemia treatment: a discussion of case histories. Nephrol Dial Transplant. 2005;20(suppl 6):vi37-vi43.
50. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant. 2001;16(suppl 7):25-28.
51. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42(5):864-881.
52. Smrzova J, Balla J, Barany P. Inflammation and resistance to erythropoiesis-stimulating agents - what do we know and what needs to be clarified? Nephrol Dial Transplant. 2005;20(suppl 8):viii2-viii7.
53. Wish JB. Can evidence drive the development of a sound national EPO reimbursement policy? [editorial]. Am J Kidney Dis. 2003;41(1):254-258.
54. Nurko S, Spirko R, Law A, Dennis V. Dosing intervals and hemoglobin control in patients with anemia of chronic kidney disease treated with erythropoiesis-stimulating agents. Am J Kidney Dis. 2007;49:A63.
55. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68(3):1337-1343.
56. Fishbane S. Recombinant human erythropoietin: has treatment reached its full potential? Semin Dial. 2006;19(1):1-4.
57. Berns JS, Fishbane S, Elzein H, et al. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients. Hemodial Int. 2005;9(3):255-263.
58. Messana T. Erythropoietin claims monitoring policy: implications for clinical practice. Nephrol Nurs J. 2006;33(2):209-213, 222.
59. Coyne DW, Kapoian T, Suki W, et al, DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007 Mar;18(3):975-984. Epub 2007 Jan 31.
60. Horl WH. Adjunctive therapy in anaemia management. Nephrol Dial Transplant. 2002;17(suppl 5):56-59.
61. Brewster UC. Intravenous iron therapy in end-stage renal disease. Semin Dial. 2006;19(4):285-290.
62. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Waraock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005 Oct;16(10):3070-3080. Epub 2005 Jul 20.
63. Gold Standard Inc. Drug monographs, Clinical pharmacology [database online]. Available at: www.clinicalpharmacology.com/Default.asp. Accessed August 15, 2007.
64. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22(7):1301-1307.
65. Singh H, Reed J, Noble S, Cangiano JL, Van Wyck DB. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis- stimulating agents for anemia: a randomized, controlled trial [published online ahead of print March 29, 2006]. CJASN ePress. 2006;1:475-482. doi: 102215/ CJN.01541005.
66. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26(5):445-454. Epub 2006 Oct 11.